 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | STSA-1005 / Staidson Biopharma, STSA-1002 / Staidson Biopharma
Trial completion date, Trial primary completion date: A Study of STSA-1002 Combined With STSA-1005 in Healthy Subjects (clinicaltrials.gov) - Dec 29, 2023
P1, N=50, Recruiting, Sponsor: Staidson (Beijing) Biopharmaceuticals Co., Ltd
Trial completion date: Dec 2023 --> Aug 2024 | Trial primary completion date: Sep 2023 --> Aug 2024
- || STSA-1005 / Staidson Biopharma, STSA-1002 / Staidson Biopharma
Enrollment open: A Study of STSA-1002 Combined With STSA-1005 in Healthy Subjects (clinicaltrials.gov) - Nov 25, 2022
P1, N=40, Recruiting, Sponsor: Staidson (Beijing) Biopharmaceuticals Co., Ltd
Trial completion date: Dec 2023 --> Aug 2024 | Trial primary completion date: Sep 2023 --> Aug 2024 Not yet recruiting --> Recruiting
- || STSA-1005 / Staidson Biopharma, STSA-1002 / Staidson Biopharma
New P1 trial: A Study of STSA-1002 Combined With STSA-1005 in Healthy Subjects (clinicaltrials.gov) - Sep 29, 2022
P1, N=40, Not yet recruiting, Sponsor: Staidson (Beijing) Biopharmaceuticals Co., Ltd
- || STSA-1005 / Staidson Biopharma
Trial completion: The Safety and Tolerability of STSA-1005 Following Intravenous Infusion in Healthy Subjects (clinicaltrials.gov) - Apr 18, 2022
P1, N=32, Completed, Sponsor: Staidson Biopharma Inc.
Not yet recruiting --> Recruiting Recruiting --> Completed
- || STSA-1005 / Staidson Biopharma
Enrollment open: The Safety and Tolerability of STSA-1005 Following Intravenous Infusion in Healthy Subjects (clinicaltrials.gov) - Oct 29, 2021
P1, N=32, Recruiting, Sponsor: Staidson Biopharma Inc.
Recruiting --> Completed Not yet recruiting --> Recruiting
- | STSA-1005 / Staidson Biopharma
New P1 trial: The Safety and Tolerability of STSA-1005 Following Intravenous Infusion in Healthy Subjects (clinicaltrials.gov) - Oct 19, 2021
P1, N=32, Not yet recruiting, Sponsor: Staidson Biopharma Inc.